Insulin secretion by pancreatic beta cell

Insulin secretion by pancreatic beta cell refers to the physiological process through which specialized endocrine cells within the islets of Langerhans detect elevated blood glucose and respond by releasing the hormone insulin. This process is primarily triggered when rising blood glucose enters beta cells via specific transporters—GLUT2 in rodents and mainly GLUT1/GLUT3 in humans—where it undergoes metabolism. The resulting increase in intracellular ATP leads to closure of ATP-sensitive potassium channels, causing membrane depolarization. This opens voltage-gated calcium channels; calcium influx then triggers exocytosis of stored insulin granules into circulation. This mechanism ensures tight regulation of blood sugar after meals but can be disrupted or dysregulated in diseases such as type 2 diabetes mellitus—where either insufficient or excessive demand on these cells leads to impaired function—or rarely overactive due to tumors like insulinoma. Pharmacologic agents such as sulfonylureas and GLP‑1 receptor agonists exploit different steps along this pathway to enhance endogenous insulin output for therapeutic benefit. Importantly, “Insulin secretion by pancreatic beta cell” describes a complex cellular function—not a discrete molecular target like an enzyme or receptor—and thus should not be considered a canonical drug target entity itself.[3][5][6]

Other names

Glucose-stimulated insulin secretionGSISBeta-cell insulin releasePancreatic beta-cell exocytosis of insulin

For drugs acting on the pathway: - Sulfonylureas close ATP-sensitive potassium channels in beta cells to trigger depolarization and calcium influx, leading to increased insulin release[1]. - GLP‑1 receptor agonists enhance glucose-dependent insulin secretion by increasing cAMP and amplifying the effect of glucose metabolism in beta cells[4].